SELLAS Life Sciences Group (NASDAQ:SLS) Trading Down 6.2% - Should You Sell?

Key Points

• SELLAS Life Sciences (NASDAQ:SLS) shares fell about 6.2% to roughly $5.46 on Wednesday, trading as low as $5.44 with ~4.13 million shares exchanged—about 51% below its average daily volume and off a prior close of $5.82.
• The stock carries a consensus "Hold" rating with a $7.00 target; analyst coverage is split (one Buy, one Sell) and Weiss Ratings recently reiterated a sell (D-) stance.
• SELLAS is a clinical-stage biopharma developing the WT1-targeted vaccine galinpepimut‑S (GPS)

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) was down 6.2% during trading on Wednesday . The company traded as low as $5.44 and last traded at $5.4580. Approximately 4,133,323 shares changed hands during mid-day trading, a decline of 51% from the average daily volume of 8,485,182 shares. The stock had previously closed at $5.82.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a "sell (d-)" rating on shares of SELLAS Life Sciences Group in a research report on Thursday, January 22nd. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $7.00.

SELLAS Life Sciences Group Trading Down 7.0%

The firm has a fifty day moving average price of $4.27 and a 200 day moving average price of $2.72. The firm has a market cap of $771.17 million, a PE ratio of -19.28 and a beta of 2.18.

Institutional Trading of SELLAS Life Sciences Group

Hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. raised its position in shares of SELLAS Life Sciences Group by 2.8% during the 3rd quarter. Vanguard Group Inc. now owns 6,839,905 shares of the company's stock valued at $11,012,000 after buying an additional 185,106 shares during the period. Anson Funds Management LP grew its position in SELLAS Life Sciences Group by 2,093.8% in the third quarter. Anson Funds Management LP now owns 6,032,938 shares of the company's stock worth $9,713,000 after acquiring an additional 5,757,938 shares during the period. Geode Capital Management LLC grew its position in SELLAS Life Sciences Group by 35.9% in the fourth quarter. Geode Capital Management LLC now owns 3,077,337 shares of the company's stock worth $11,604,000 after acquiring an additional 812,953 shares during the period. Marshall Wace LLP increased its stake in SELLAS Life Sciences Group by 23,550.0% during the second quarter. Marshall Wace LLP now owns 2,715,489 shares of the company's stock worth $5,947,000 after acquiring an additional 2,704,007 shares during the last quarter. Finally, State Street Corp raised its position in SELLAS Life Sciences Group by 60.8% in the fourth quarter. State Street Corp now owns 2,188,171 shares of the company's stock valued at $8,249,000 after purchasing an additional 827,257 shares during the period. Institutional investors and hedge funds own 17.38% of the company's stock.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms' tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient's own immune system to recognize and attack WT1-positive cancer cells.

The company's lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.